Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Friday, November 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus reported that more than half of patients with refractory microsatellite-stable metastatic colorectal cancer achieved long-term survival after receiving botensilimab and balstilimab. The company shared these results from the Phase 1b C-800-01 trial at the SITC 2026 meeting. The data focused on heavily pretreated patients without active liver metastases.

Market Sentiment Analysis

POSITIVE FACTORS

  • More than half of patients achieved long-term survival.
  • Results from a Phase 1b trial show promising outcomes.
  • Combination therapy of BOT and BAL is innovative.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
5.5%
average across 3 past catalysts
Cash runway
~13 mo
Medium dilution risk
Lead asset
AGEN2034
Phase 2 · Advanced Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were prese

Frequently Asked Questions

What is the C-800-01 trial?

The C-800-01 trial evaluates botensilimab and balstilimab in mCRC patients.

What type of cancer was studied?

The study focused on refractory MSS metastatic colorectal cancer.

What were the results of the trial?

Over half of the patients achieved long-term survival.

What is the significance of the findings?

The results suggest a promising treatment option for heavily pretreated patients.

ShareAdd on Google
Tags: AGEN Agenus botensilimab balstilimab mCRC Phase 1b trial
Last updated: Nov 6, 2026

Biotech snapshot

Cash runway
$87M liquidity · $7M/mo burn
~13 mo
Medium dilution risk
Lead asset
AGEN2034Phase 2
Advanced Cancer →

Catalyst track record

+203%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →